Abstract 571P
Background
Brain metastases (BM) are common among EGFRm NSCLC patients. And it has been associated with treatment failure and limited survival especially patients with multiple BMs. Dacomitinib is a selective, irreversible, Pan-HER TKI. It brought significant PFS and OS improvement compared with Gefitinib in phase 3 randomize study ARCHER 1050. However, patients with BM or leptomeningeal metastases were excluded in this study. We hereby conducted this phase II study (NCT02047747) to prospectively evaluate the efficacy and safety of Dacomitinib in NSCLC patients with multiple BMs and here are initial results of this study.
Methods
Treatment-naive stage IIIB/IV EGFR-mutant NSCLC patients with multiple and measurable BMs(≥ 3 metastatic lesions in the brain and at least 1 target lesion’s diameter among these lesions should be ≥1 cm) received Dacomitinib45mg orally once daily. Assessments were performed every8 weeks until disease progression (PD) as per RECIST v1.1. End points included PFS, intracranial ORR (iORR), ORR, and safety.
Results
At data cut-off (Jul 1, 2023), a total of 14 patients were enrolled and the median follow-up time was 24 months (range, 4-28m), of which 10 patients had measurable CNS response. For all patients, the mPFS was 15.3m(8/14),ORR was 78.6% while DCR was 100%.The iORR was 80% and iDCR was 100%. The mPFS in patients with 19Del (8/14,57.1%) and21L858R (6/14,42.9%) are 15.3 and 15.2m, ORR are 87.5% and 66.7%, respectively. There are no new adverse events (AEs) compared to ARCHER1050.The most common AEs were rash (10/14; 71.4%), diarrhea (8/14; 57.1%), paronychia (3/14; 21.4%). Temporary discontinuations and dose modification occurred in 2 (14.3%) and 1 (7.1%) patient, respectively.
Conclusions
Dacomitinib showed promising intracranial antitumor activity with a manageable safety profile as first-line therapy in EGFR-mutant NSCLC patients with multiple brain metastases.
Clinical trial identification
NCT02047747.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Funding
Pfizer.
Disclosure
Y. Yu: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Rohce, MSD. Y. Pan: Financial Interests, Personal, Advisory Board: Pfizer, AstraZeneca, Roche, MSD; Financial Interests, Personal, Invited Speaker: Pfizer. J. Zhou: Financial Interests, Personal, Invited Speaker: Pfizer, AstraZeneca, Roche, MSD. S. Lu: Financial Interests, Institutional, Invited Speaker: Hansoh, AstraZeneca, Roche, Hengrui; Financial Interests, Institutional, Advisory Board: AstraZeneca, Prizer, Boehringer Ingelheim, Hutchison MediPharma, ZaiLab, GenomiCare, Yuhan Corporation, Menarini, InventisBio Co.Ltd, Roche, Simcere Zaiming Pharmaceutical Co., Ltd.; Financial Interests, Personal, Research Grant: AstraZeneca, Hutchison, BMS, Heng Rui, Roche, Hansoh, BeiGene, Lilly Suzhou Pharmaceutical Co.Ltd; Financial Interests, Personal, Coordinating PI: FibroGen.
Resources from the same session
414P - Landscape of ERBB2 mutations in advanced cancers (AC) using circulating tumor DNA (ctDNA) next-generation sequencing (NGS) in Asia and Middle East (AME)
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract